Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression [5]

Journal of Clinical Psychiatry

Volumn 66, Issue 4, 2005, Pages 544-

  Galynker, Igor ^a   Khan, Asim ^a   Grebchenko, Yuli ^a   Ten, Aleksey ^a   Malaya, Liliya ^a   Yanowitch, Philip ^a   Cohen, Lisa J ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR;

ADULT; AGED; ANXIETY DISORDER; CLINICAL ARTICLE; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; HAMILTON SCALE; HUMAN; LETTER; LOW DRUG DOSE; MALE; MONOTHERAPY; PRIORITY JOURNAL; SCORING SYSTEM; TARDIVE DYSKINESIA;

EID: 17844384210     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v66n0420f     Document Type: Letter

References (7)

1. Gorwood P. Generalized anxiety disorder and major depressive disorder comorbidity: an example of genetic pleiotropy? Eur Psychiatry 2004;19:27-33
2. Kaplan M. Atypical antipsychotics for treatment of mixed depression and anxiety [letter]. J Clin Psychiatry 2000;61:388-389
3. Adson DE, Kushner MG, Eiben KM, et al. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety 2004;19:121-126
4. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
5. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
6. Leysen JE, Janssen PMF, Megens AAHP, et al. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994;55(suppl 5):5-12
7. 2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 2001;11:105-110